Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdVince in Metastatic Neuroendocrine Tumors
NCT02749331Phase 2Active, not recruiting
- Sponsor
- Uppsala University
- Start
- Mar 2016
- Primary completion
- Aug 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of AdVince in neuroendocrine tumors (NETs), sponsored by Uppsala University. Started Mar 2016; status: active, not recruiting.
02
Drugs
AdVince
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT02749331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02749331.